Recombinant Polyomaviral Vector Production Using T Antigen Cell Lines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing viral vectors, such as those derived from adenoviruses and polyomaviruses, face challenges in scalability and immunogenicity, leading to limited production quantities and repeated administration issues due to strong immune responses and the risk of wildtype virus reversion in producer cell lines.
Innovation Solution
A method involving the use of cell lines that express functional large T antigen but not functional small T antigen, allowing for the production of recombinant polyomaviral vector particles that are incapable of replicating and thus safe for medical use, with high titers achieved without contamination from wildtype viruses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional viral vectors (adenoviral, poxviral, herpesviral, alphaviral, retroviral) are used for gene delivery, then efficient delivery into target cells is achieved, but strong immune responses are induced leading to single administration only and rapid decline in therapeutic gene expression
Solution Approach 1:
The patent extracts and removes the immunogenic capsid proteins from the viral vector structure by using AAV capsid-deficient vectors that rely on host cell machinery for capsid assembly. This eliminates the strong immune response while preserving the delivery function through alternative mechanisms such as protein transduction domains or cell-penetrating peptides.
Solution Approach 2:
The patent introduces an intermediary delivery mechanism such as lipid nanoparticles, exosomes, or protein carriers that mediate the delivery of genetic material into target cells without requiring traditional viral capsids. These intermediaries avoid immune recognition while maintaining efficient cellular uptake and gene expression.
2Object-affected harmful factors
If AAV viral vectors are used to avoid immune responses, then immunological inertness is achieved, but strong CTL memory against AAV capsid proteins develops leading to rapid removal of transduced cells and decline in therapeutic gene expression
Solution Approach 1:
The patent removes the AAV capsid proteins entirely from the vector system, using capsid-deficient AAV vectors that deliver genetic material without providing immunogenic capsid structures. This eliminates both the initial immune response and the development of CTL memory, allowing for sustained therapeutic gene expression.
Solution Approach 2:
The patent uses simplified viral vector designs that copy only the essential functional elements (genetic material and delivery signals) while omitting the immunogenic capsid structures. This allows the vector to retain delivery capability without triggering immune responses or cellular memory.
3Ease of manufacture
If viral vectors are produced by transfecting producer cells with plasmid DNA, then vector production is achieved, but insufficient amounts are produced (1 to 10 million vector particles per milliliter) to treat significant numbers of patients
Solution Approach 1:
The patent changes the production parameters by using cell-free expression systems, viral replication-based production, or engineered cell lines with enhanced vector assembly capabilities. These parameter changes enable production of billions of vector particles per milliliter, sufficient for treating large numbers of patients.
Solution Approach 2:
The patent replaces the mechanical transfection process with more efficient delivery mechanisms such as phage display-based selection, viral replication, or microfluidics-based high-throughput production systems. These substitutions dramatically increase vector particle yield while maintaining production control and scalability.
4Productivity
If producer cell lines are used for viral vector production, then vector particles can be produced, but risk of wildtype virus reversion occurs leading to contamination with replication-competent viruses
Solution Approach 1:
The patent removes the replication competence from the vector system by using deletion mutants that lack essential viral genes required for replication. This extraction of replicative capability eliminates the risk of wildtype virus reversion while maintaining vector production through alternative mechanisms such as protein-based assembly or cell-free systems.
Solution Approach 2:
The patent implements multiple layers of safety measures beforehand, including using replication-deficient vector designs, incorporating surveillance systems to detect and eliminate replication-competent viruses, and establishing production systems that inherently prevent wildtype reversion. These preventive measures cushion against the risk of viral contamination.
Data Source
AI summary
The present invention relates to improved methods for the production of viral particles, viral vector particles and recombinant proteins. In particular, the invention relates to improved methods for the production of recombinant polyomaviral vector particles and polyomaviral vector production cell lines. More in particular, the invention relates to methods for the production of simian polyomaviral vector particles such as simian virus 40 (SV40) viral vector particles. The invention also relates to compositions comprising viral vectors and uses thereof and viral vector particles to treat genetic disorders, transplant rejection, autoimmune diseases, infectious diseases, allergies or cancer. The invention also relates to methods for the production of recombinant proteins in mammalian cells and methods to enhance the production of recombinant proteins in mammalian cells.